About

5th Gamma Delta T Cell Therapies Summit - What's It About?

Gamma Delta T Therapies continue to spark interest whereby their unique biological features are being targeted to better tackle solid tumors. In 2024, the community is poised at a pivotal juncture, intensifying efforts to comprehensively grasp the clinical safety and efficacy of gamma delta T therapies. This summit aims to solidify confidence in the transformative potential of this approach within the realms of cell therapy and antibody development. 

Bootcamp
Day

Explores past and present clinical insights to forecast future therapeutic directions, the potential of epigenetic reprogramming to maximize therapeutic efficacy, implementing best practices in manufacturing gamma delta T cells for quality, scalability, and safety in clinical applications

Research & Translational Development

Explore how to fine tune mechanisms of gamma delta T cells for precise solid tumor targeting and treating autoimmune diseases 

Clinical Development & Product Optimization

Discover the best practises when organising clinical trial design and appeasing regulators to fast track pipelines into the clinic and beyond 

What You Can Expect...............................................................................................

What You Can Expect

Secondary 3
Secondary 3

Detailing their clinical updates across all autologous and allogeneic products: DeltEx DRI Auto, DeltEx Allo, DeltEx nsCAR-T INB-300 & iPSC Derived Gamma-Delta T Cells

Secondary 3 (1)
Secondary 3 (1)

Clinical design case study on best practice when designing and running a CAR-T clinical trial in autoimmune and oncology indications

Secondary 3 (2)
Secondary 3 (2)

Presenting latest clinical findings on Vd2 and Vd1 gamma delta T cells that evaluate the efficacy, safety and benefits of why gamma delta cell therapies are effective in treating AcutAML

Secondary 3 (3)
Secondary 3 (3)

Presenting novel preclinical dual CAR architecture targeting and engineering gamma delta T cells to establish an allogeneic dual targeting CAR that will consist of CSPG4 and CD70 

Secondary 3 (6)
Secondary 3 (6)

Reviewing the development of their off-the-shelf lead product and setting up current UK based clinical trials

Secondary 3 (7)
Secondary 3 (7)

Introduction to the Immunocore ImmTAX discovery platform and the first approved gamma delta TCR bi-specific therapeutic 

“There was an excellent mix of academia and drug developer folks, so this is a great venue of learning gdT cell biology and the progress of developing gdT cell therapies”

Associate Principal Scientist, Merck & Co  - Past Delegate